EC Microbiology

Introduction: In order to prolong the life of babies and reduce neonatal and maternal mortality rates, antibiotics are being used sporadically. Pregnant patients in certain situations face life-threatening infections, warranting the use of antibiotics. Apart from an alteration in drug pharmacokinetics, risk of teratogenic potential and toxicity to developing fetus needs to be studied extensively. Some data suggests the even with antibiotics considered safe in pregnancy, long term childhood obesity and compromised immunity in children is seen. Enhanced cardiac output, increased glomerular filtration rate and an increase in total body volume are some of the common physiological changes seen in pregnancy. These changes influence the pharmacokinetics and drug interaction and require careful dose adjustment and monitoring. More research and data need to be collected to ascertain the safety of antibiotics used in pregnancy.

Aim and Work:An overview of antibiotic use in the first trimester of pregnancy. The Classification of drugs and antibiotics gener- ally considered safe in the first trimester

Methodology:The review is comprehensive research of PUBMED from year 1941 to 2017.

Conclusion:A complete knowledge of the safety and side effects of the drugs used in pregnant and lactating women is absolutely necessary. The teratogenic potential and toxic risk profile of all drugs must be taken into consideration, and a risk to benefit analysis must be done before prescribing antibiotics. The first trimester is the stage of organogenesis, and with major implications on the unborn fetus is the drug crosses the placenta.

 Keywords: Antibiotics in Pregnancy; Safe Antibiotics; Teratogenicity; Drugs in Pregnancy

1. Mitchell AA., et al. “Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008”. American Journal of Obstetrics and Gynecology 205.1 (2011): 51.e1-e8.
2. Dashe JS and Gilstrap III L C. “Antibiotic use in pregnancy”. Obstetrics and Gynecology Clinics of North America 24.3 (1997): 617-629.
3. Sannerstedt R., et al. “Drugs during pregnancy”. Drug Safety 14.2 (1996): 69-77.
4. Harbison AF., et al. “Antiinfective therapy for pregnant or lactating patients in the emergency department”. American Journal of Health- System Pharmacy 72.3 (2015): 189-197.
5. Costantine M. “Physiologic and pharmacokinetic changes in pregnancy”. Frontiers in Pharmacology 5 (2014): 65.
6. Anderson G D. “Pregnancy-induced changes in pharmacokinetics”. Clinical Pharmacokinetics 44.10 (2005): 989-1008.
7. Frederiksen MC. “Physiologic changes in pregnancy and their effect on drug disposition”. Seminars in Perinatology 25.3 (2001): 120- 123.
8. Muanda F T., et al. “Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study”. British Journal of Clinical Pharmacology 83.11 (2017): 2557-2571.
9. Bookstaver PB., et al. “A review of antibiotic use in pregnancy”. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35.11 (2015): 1052-1062.
10. Singh Omkar., et al. “Drugs in pregnancy: An update”. Journal of South Asian Federation of Obstetrics and Gynecology 6.3 (2014): 7-11.
11. Gregg N M. “Congenital cataract following German measles in the mother”. In Problems of Birth Defects. Springer, Dordrecht (1941): 170-180.
12. McBride W G. “Thalidomide and congenital abnormalities”. Lancet 278.7216 (1961): 1358.
13. Yoshioka H., et al. “Placental transfer of gentamicin”. The Journal of Pediatrics 80.1 (1972): 121-123.
14. Robinson G C and Cambon K G. “Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy”. New England Journal of Medicine 271.18 (1964): 949-951.
15. Voogd C E., et al. “The mutagenic action of nitroimidazoles I. Metronidazole, nimorazole, dimetridazole and ronidazole”. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 26.6 (1974): 483-490.
16. Rustia M and Shubik P. “Induction of lung tumors and malignant lymphomas in mice by metronidazole”. Journal of the National Cancer Institute 48.3 (1972): 721-729.
17. Cohen SM., et al. “Carcinogenicity of 5 nitrofurans, 5 nitroimidazoles, 4 nitrobenzenes, and related compounds”. Journal of the National Cancer Institute 51.2 (1973): 403-417.
18. Anthony J R. “Effect on deciduous and permanent teeth of tetracycline deposition in utero”. Postgraduate Medicine 48.4 (1970): 165- 168.
19. Witkop CJ and Wolf RO. “Hypoplasia and intrinsic staining of enamel following tetracycline therapy”. Journal of the American Medical Association 185.13 (1963): 1008-1011.
20. Burns LE., et al. “Fatal circulatory collapse in premature infants receiving chloramphenicol”. New England Journal of Medicine 261.26 (1959): 1318-1321.
21. Diamond I and Schmid R. “Experimental bilirubin encephalopathy. The mode of entry of bilirubin-14C into the central nervous sys- tem”. The Journal of Clinical Investigation 45.5 (1966): 678-689.
22. Silverman WA., et al. “A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylac- tic antibacterial regimens”. Pediatrics 18.4 (1956): 614-625.